Table 2. Characteristics of patients at baseline prior to commencing treatment.
| Characteristics | No. of patients (%) (N=37) |
|---|---|
|
Age (years) | |
| Median (range) | 56 (30–83) |
|
Sex | |
| Males | 20 (54%) |
| Females | 17 (46%) |
|
Stage | |
| M1b | 2 (5%) |
| M1c | 35 (95%) |
|
LDH (ULN=220 U l−1) | |
| <ULN | 5 (14%) |
| ⩾ULN | 32 (86%) |
|
BRAF | |
| Positive | 5 (14%) |
| Negative | 31 (84%) |
| Unknown | 1 (2%) |
|
NRAS | |
| Positive | 5 (13%) |
| Negative | 8 (22%) |
| Unknown | 24 (65%) |
|
Dose of pembrolizumab | |
| 10 mg kg−1 2 weekly | 11 (30%) |
| 10 mg kg−1 3 weekly | 19 (51%) |
| 2 mg kg−1 3 weekly | 7 (19%) |
Abbreviations: LDH=lactate dehydrogenase; ULN=upper limit of normal.